First-in-Human trial launches for 'Living Drug' aiming to tame severe lupus
Disease control
Not yet recruiting
This is an early-stage safety study testing a new type of cell therapy called KN5501 for adults with moderate to severe, hard-to-treat systemic lupus erythematosus (SLE). Researchers will give patients an infusion of specially engineered immune cells designed to target and reduce…
Phase: PHASE1 • Sponsor: Ruitherapeutics Co., LTD • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC